ReviewCureus2026
A Comprehensive Review of SURGICEL®: Efficacy, Applications, and Radiological Insights in Surgery.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SURGICEL® is a widely used hemostatic material designed to control capillary, venous, and small arterial bleeding. Introduced in 1960, it functions by producing cellulosic acid, which promotes platelet aggregation and activation of the coagulation pathway. This bioabsorbable material has been utilized in various surgical procedures to manage perioperative bleeding. The objective of this article is to review the mechanism of action, clinical applications, and imaging characteristics of SURGICEL®, as well as its role in differential diagnosis in surgical contexts. This article serves as a comprehensive review of SURGICEL® in various surgical fields, including neurosurgery, urology, orthopedics, and maxillofacial surgery, while also examining SURGICEL®'s hemostatic mechanism, clinical efficacy, and bioabsorbable properties. The review also evaluates its radiological appearance in ultrasound, CT, and MRI, and addresses its role in differential diagnosis and potential complications, such as granuloma formation and infections, based on existing literature. SURGICEL® has proven effective in achieving hemostasis in a wide range of surgical procedures, including maxillofacial and neurosurgical operations. As a bioabsorbable material, it induces minimal tissue reactions and is gradually absorbed over time. On imaging, it appears as echogenic masses, radiopaque bands, or alterations in signal intensity, particularly on MRI. MRI can differentiate SURGICEL® from adjacent tissues, aiding in the identification of hematoma-like masses or complications such as granulomas and infections. Overall, SURGICEL® offers significant utility in surgical hemostasis with minimal side effects. However, careful monitoring is required to avoid complications, and knowledge of its radiological appearance is essential for accurate differential diagnosis. This review highlights its coagulation-promoting properties, imaging features, and potential complications to guide its effective clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.